CDH1 and non-small cell lung carcinoma: Furthermore, long-term supplementation with compound 19 partially represses and reverses EMT, i.e., restores E-Cadherin expression, and EMT triggers the metastatic and drug-resistance properties of cisplatin-resistant NSCLC cells.